Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5241MR)

This product GTTS-WQ5241MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5241MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5915MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ14961MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ5305MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ15817MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ11126MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ11981MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ11730MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ13715MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW